Effects of treatment of secondary hyperparathyroidism on the lipid profile in patients on hemodialysis

Blood Purification

Volumn 16, Issue 1, 1998, Pages 22-29

  Lim, Paik Seong ^a   Hung, Tung Shiao ^a   Yeh, Chi Hsiang ^a   Yu, Mei Huri ^a  

^a KUANG TIEN GENERAL HOSPITAL   (Taiwan)

Author keywords

Dyslipidemia; Hemodialyis; Pulse calcitriol therapy; Secondary hyperparathyroidism

Indexed keywords

ALKALINE PHOSPHATASE; APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BICARBONATE; CALCITRIOL; CALCIUM ION; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHORUS; TRIACYLGLYCEROL; UREA;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; HYPERLIPOPROTEINEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; ORAL DRUG ADMINISTRATION; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL;

ADMINISTRATION, ORAL; ADULT; AGED; CALCITRIOL; FEMALE; HUMANS; HYPERPARATHYROIDISM; LIPIDS; MALE; MIDDLE AGED; RENAL DIALYSIS; UREMIA;

EID: 0031893666     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000014309     Document Type: Article

References (41)

1. Norbeck HE, Oro L, Carlson LA: Serum lipid and lipoprotein concentrations in chronic uremia. Acta Med Scand 1976;200:487-492.
2. Bagdade JD, Porte D, Bierman EL: Hypertriglyceridemia: A metabolic consequence of chronic renal failure N Engl J Med 1968;279:181-185.
3. Attman PO, Alaupovic P: Lipid abnormalities in chronic renal insufficiency. Kidney Int 1991;39(suppl): 16-23.
4. Grutzmacher P, Marz W, Peschke B, Gross W, Schoeppe W: Lipoproteins and apolipoproteins during the progression of renal disease. Nephron 1988;50:103-111.
5. Nestel PJ, Fidge NH, Tan MH: Increased lipoprotein-remnant formation in chronic renal failure. N Engl J Med 1982;307:329-333.
6. Rapoport J, Aviram M, Chaimovitz C, Brook JG: Defective high-density lipoprotein composition in patients on chronic hemodialysis: A possible mechanism for accelerated atherosclerosis. N Engl J Med 1978;299: 1326-1329.
7. Avram MM, Fein PA, Antignani A, Mittman N, Mushnick RA, Lustig AR, Lapuz MH: Cholesterol and lipid disturbances in renal disease: The natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis. Am J Med 1989;87; 55N-60N.
8. Joven J, Rubies-Prat J, Espinel E, Chacon P, Olmos A, Masdeu S: Apoprotein A-I and high density lipoprotein subfractions in patients with chronic renal failure receiving hemodialysis. Nephron 1985;40: 451-454.
9. Goldberg AP, Harter HR, Patsch W, Schechtman KB, Province M, Werts C, Kuisk I, McCrate MM, Schonfeld G: Radical differences in plasma high-density lipoprotein in patients receiving hemodialysis: A possible mechanism for atherosclerosis in white men. N Engl J Med 1983;308: 1245-1252.
10. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H: Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int 1992;41:1653-1661.
11. Werner S, Low H: Stimulation of lipolysis and calcium accumulation by parathyroid hormone in rat adipose tissue in vitro after adrenalectomy and administration of high doses of cortisone acetate, Horm Metab Res 1973;5:292-296.
12. Gozariu L, Forster K, Faulhaber JD, Minne H, Ziegler R: Parathyroid hormone and calcitonin: Influences upon lipolysis of human adipose tissue. Horm Metab Res 1974;6:243-245.
13. Ziegler R, Jobst W, Minne H, Faulhaber JD: Calcitropic hormones and lipolysis of human adipose tissue: Role of extracellular calcium as conditioning but not regulating factor. Endokrinologie 1980; 75:577-588.
14. Sinhha TK, Thajchayapon GP, Queener SF, et al: On the lipolytic action of parathyroid hormone in man. Metabolism 1976;25:251-260.
15. Cantin M: Kidney, parathyroid and lipidemia. Lab Invest 1965;14: 1691-1698.
16. Alfrey AC, Tomford RC. Karlinsky ML: Effect of parathyroidectomy on nephrotic serum nephritis. Kidney Int 1980;18:430.
17. Ritz E, Heuck CC, Boland R: Phosphate, calcium and lipid metabolism. Adv Exp Med Biol 1980;128: 197-208.
18. Akmal M, Kasim SE, Soliman AR, Massry SG: Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int 1990;37:854-858.
19. Lacour B, Roullet JB, Liagre AM, Jorgetti V, Beyne Pdubost C, Drücke T: Serum lipoprotein disturbances in primary and secondary hyperparathyroidism and effects of parathyroidectomy. Am J Kidney Dis 1986;8:422-429.
20. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984;74:2136-2143.
21. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrerd DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989;321:274-279.
22. 3. Nephron 1991;58:288-294.
23. 3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 1991;57:23-28.
24. Fischer ER, Harris DCH: Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 1993;40: 216-220.
25. Liou HS, Chiang SS, Huang TP, Shieh SD, Akmal M: Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients. Miner Electrolyte Metab 1994;20:97-102.
26. Martin KJ, Ballal S, Domoto DT, Blalock S, Weindel M: Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis: Preliminary observations. Am J Kidney Dis 1992;19:540-545.
27. Delmez J: Calcitriol and secondary hyperparathyroidism in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1993; 13:95-97.
28. Juergensen P, Santacroce S, Mooraki A, Cooper K, Finkelstein FO, Kliger AS: Pulse oral calcitriol to treat hyperparathyroidism in 43 patients. Adv Perit Dial 1994;10:259-260.
29. Attman PO, Alaupovic P: Lipid and apolipoprotein profiles of uremic dyslipoproteinemia: Relation to renal function and dialysis. Nephron 1991;57:401-410.
30. Attman PO, Samuelsson O, Alaupovic P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993;21:573-592.
31. Fidge N, Nestel P, Toshitsugu I, Reardon M, Billington T: Turnover of apoproteins A-I and A-II of high density lipoprotein and the relationship to other lipoproteins in normal and hyperlipidemic individuals. Metabolism 1980;29:643-653.
32. Saku K, Gartside PS, Hynd BA, Mendoza SG, Kashyap M: Apolipoprotein A-I and A-II metabolism in patients with primary high density lipoprotein deficiency associated with familial hypertriglyceridemia. Metabolism 1985;34:754-764.
33. Golay A, Zech L, Shi M-Z, Chiou Y-AM, Reaven GM, Chen Y-DI: High density lipoprotein (HDL) metabolism in non-insulin-dcpcndcnt diabetes mellitus: Measurement of HDL turnover using tritiated HDL. J Clin Endocrinol Metab 1987;65: 512-518.
34. Nikkila EA, Taskinen M-R, Kekki M: Relation of plasma high-density lipoprotein cholesterol and lipoprotein lipase activity in adipose tissue and skeletal muscle of man. Atherosclerosis 1978;29:497-501.
35. Eisenberg S: High density lipoprotein metabolism. J Lipid Res 1984; 25:1017-1058.
36. Dieplinger H, Schoenfeld PY, Fielding CJ: Plasma cholesterol metabolism in end-stage renal disease: Difference between treatment by hemodialysis or peritoneal dialysis. J Clin Invest 1986;77:1071-1083.
37. Mendez AG, Perez GO, Hsia SL: Defect in cholesteryl ester transport in serum of patients with uremia receiving maintenance hemodialysis: Increased inhibitor activity for cholesterol ester transfer. J Lab Clin Med 1988;111:677-683.
38. Fuh M, Lee C-M, Jeng C-Y, Shen DC, Shieh SM, Reaven GM, Chen EDI: Effect of chronic renal failure on high-density lipoprotein kinetics. Kidney Int 1990;37:1295-1300.
39. Kamanna VS, Kashyap ML, Pai R, Bui DT, Jin FY, Roh DD, Shah GM, Kirshenbaum MA: Uremic serum subfraction inhibits apolipoprotein A-I production by a human hepatoma cell line. J Am Soc Nephrol 1994;5:193-200.
40. Varizi ND, Wellikson L, Gwinup G, Byrne C: Lipid fractions in primary hyperparathyroidism before and after surgical cure. Acta Endocrinol (Copenh) 1983;102:539-542.
41. 3 treatment on lipid levels in uremic hemodialysis patients. Int J Artif Organs 1992; 15:704-707.